Explore

Rapid Read Rapid Read
NYU Langone Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49% Over Five Years

NYU Langone Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49% Over Five Years

A study led by NYU Langone Health has demonstrated that a combination of the intismeran vaccine and pembrolizumab significantly reduces the risk of melanoma recurrence and death by 49% over five years. The phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The combination therapy showed a 68.8% cancer-free rate compared to 49.1% in the pembrolizumab-alone group. The study, presented at the ASCO 2026 Annual Meeting, highlights the potential of mRNA vaccines in enhancing immunotherapy effectiveness against melanoma.
Rapid Read Rapid Read
New Studies Highlight Advances in Treatment for Relapsed Blood Cancer

New Studies Highlight Advances in Treatment for Relapsed Blood Cancer

Two significant studies presented at the American Society of Clinical Oncology meeting in Chicago have revealed promising advancements in the treatment of relapsed multiple myeloma, a type of blood cancer. The first study focused on mezigdomide, an oral drug that, when combined with other treatments, significantly improved progression-free survival rates. The second study examined Teclistamab, an immunotherapy that showed a substantial reduction in disease progression and death risk. These studies indicate a shift towards more effective and less burdensome treatment options for patients who have relapsed after initial therapies.
Rapid Read Rapid Read
Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T therapy, LB2501, has achieved a 100% response rate in a Phase 1 study of non-Hodgkin lymphoma. All six patients treated with the therapy responded, with five achieving complete remission. The study's results position Legend Biotech as a potential takeover target in the competitive CAR T market. The therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or serious adverse events reported. The trial is ongoing, with further data expected in the coming years.
Rapid Read Rapid Read
GLP-1 Drugs Show Potential Benefits in Cancer Treatment

GLP-1 Drugs Show Potential Benefits in Cancer Treatment

Recent studies presented at the American Society of Clinical Oncology meeting suggest that GLP-1 drugs, commonly used for diabetes and weight loss, may offer protective benefits against various cancers. Research involving over 12,000 patients indicates that these drugs are associated with lower risks of cancer progression and improved survival rates, particularly in lung, breast, colorectal, and liver cancers. The studies also suggest that GLP-1 drugs may enhance the effectiveness of immunotherapies. While the exact mechanisms remain unclear, researchers believe the drugs' anti-inflammatory properties and effects on insulin signaling may contribute to these benefits.
Rapid Read Rapid Read
NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

A study led by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of a vaccine, intismeran, and the immunotherapy drug pembrolizumab (Keytruda) can significantly reduce the risk of melanoma recurrence and death. The phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The results, presented at the 2026 annual meeting of the American Society of Clinical Oncology, showed that the combination therapy reduced the risk of cancer recurrence or death by 49% compared to the standard treatment of pembrolizumab alone. Additionally, the combination therapy reduced the risk of distant metastasis by 59%. The study highlights the potential of mRNA vaccines like intismeran in enhancing the effectiveness of immunotherapy for cancers with high mutation rates.
Rapid Read Rapid Read
mRNA Vaccine for Melanoma Shows Significant Efficacy in Preventing Recurrence

mRNA Vaccine for Melanoma Shows Significant Efficacy in Preventing Recurrence

A recent study has shown that a personalized mRNA vaccine, developed by Moderna in collaboration with Merck, is highly effective in preventing the recurrence of melanoma when used alongside the immunotherapy drug Keytruda. The trial, which included 157 patients from the U.S. and Australia, demonstrated that the combination therapy reduced the risk of cancer recurrence by 49% over five years. The vaccine is tailored to each patient's tumor, using mRNA technology to train the immune system to recognize and attack specific neoantigens associated with the cancer. This approach has shown promising results, with 68.8% of patients remaining cancer-free after five years, compared to 49.1% who received only Keytruda.
Rapid Read Rapid Read
NYU Langone Health Study Shows mRNA Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows mRNA Vaccine Reduces Melanoma Recurrence by 49%

A recent study conducted by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of an mRNA-based vaccine, intismeran, and the immunotherapy drug pembrolizumab significantly reduces the risk of melanoma recurrence and death. The study involved 107 patients who had undergone melanoma surgery and were randomly selected to receive the combination therapy. Results showed a 49% reduction in the risk of cancer recurrence or death compared to a control group receiving only pembrolizumab. The study, known as KEYNOTE-942, was presented at the American Society of Clinical Oncology's annual meeting and published in the Journal of Clinical Oncology. The vaccine works by teaching the immune system to recognize and attack cancer cells, utilizing T cells to target specific neoantigens produced by melanoma cells.
Rapid Read Rapid Read
Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

A clinical trial has demonstrated the potential of a personalized mRNA vaccine in reducing the recurrence of melanoma. Conducted by researchers at NYU Langone Health, the trial involved 157 patients in Australia and the U.S. who had undergone surgery to remove their tumors. The study combined the mRNA vaccine with Keytruda, an immunotherapy drug, and showed that 68.8% of patients remained cancer-free after five years, compared to 49.1% who received Keytruda alone. The results, presented at the American Society of Clinical Oncology conference, highlight the vaccine's ability to train T cells to recognize and target specific neoantigens, enhancing the immune system's response to cancer.
Rapid Read Rapid Read
New Hormone Therapy Regimen Shows Promise for Prostate Cancer Surgery Patients

New Hormone Therapy Regimen Shows Promise for Prostate Cancer Surgery Patients

A new phase 3 clinical trial suggests that a combination of hormone therapies before and after prostate cancer surgery may improve outcomes for patients with high-risk, early-stage prostate cancer. The PROTEUS trial found that this regimen was superior to the standard approach of using a single hormone therapy. The study's results are being interpreted as a potential new standard of care, with experts highlighting its significance in improving survival rates and quality of life for prostate cancer patients.
Trendline Trendline
Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial

Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial

Eli Lilly's Retevmo Shows Promise in Early-Stage Lung Cancer Trial
Trendline Trendline
Revolution Medicines' Daraxonrasib Shows Promise in Pancreatic Cancer Treatment

Revolution Medicines' Daraxonrasib Shows Promise in Pancreatic Cancer Treatment

Revolution Medicines' Daraxonrasib Shows Promise in Pancreatic Cancer Treatment
Trendline Trendline
Tempus AI Unveils Multimodal Foundation Model for Oncology Insights at ASCO 2026

Tempus AI Unveils Multimodal Foundation Model for Oncology Insights at ASCO 2026

Tempus AI Unveils Multimodal Foundation Model for Oncology Insights at ASCO 2026